Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference24 articles.
1. A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive HER2 normal patients with residual disease after neoadjuvant chemotherapy and surgery [Internet].: Clinical Trials.gov; 2018 [updated February 28, 2018]. https://clinicaltrials.gov/ct2/show/NCT01864746?id=NCT01864746+OR+NCT02445391+OR+NCT03011060&rank=3&load=cart. Accessed 25 Oct 2018
2. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21(22):4165–4174
3. Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R et al (2014) Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 32(34):3883–3891
4. Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM et al (2016) Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2(6):751–760
5. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献